June 15, 2026 TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 15, 2026 Activision Blizzard, Inc. Notice of June 30, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
June 15, 2026 Positive Group LLC Addresses Dating Myths With Educational Resource on Herpes Relationships
June 15, 2026 FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
